Kathleen Kennedy Townsend Secures Buyer for 16 Million Cape Cod Property Amid Strong Coastal Real Estate Demand Consumers Spend More in April Despite Elevated Gas Prices Latest Data Shows Arabica Coffee Futures Surge to AllTime High as USColombia Tariff Tensions Ease Ebola Risk in DR Congo Raises Concerns for Regional Markets and Supply Chains RBI Dividend and Geopolitical Tensions Set the Stage for Indian Markets This Week CJ Expands KCulture Push From Bibigo Dumplings to Premium Korean Spirits at Byron Nelson Cosmos Health Inc Q1 2026 Earnings Deep EPS Miss Raises Concerns Amid Thin Revenue Disclosure CLDX Q1 2026 Earnings Clinicalstage biotech reports widerthanexpected loss as pipeline investment continues FELE Q1 2026 Earnings EPS Surges Past Estimates Amid Strong Execution BSET Q1 2026 Earnings EPS Falls Short of Estimates Amid Challenging Furniture Market Talos Energy Q1 2026 Earnings EPS Beat Drives Positive Market Sentiment Arcturus Therapeutics Holdings Inc ARCT Q1 2026 Earnings Narrower Net Loss Beats Estimates Amid Pipeline Progress DWave Quantum QBTS Surges 14 as Quantum Computing Momentum Builds Prairie Operating Co PROP Extends Decline as Shares Test Key Support Near 089 Brighthouse Financial Preferred Stock BHFAO Edges Higher as Support Holds Hesai Group HSAI Slips 129 as Lidar Sector Faces Headwinds Support at 196 Under Watch Armada Acquisition Corp II Warrants XRPNW Shed 1579 as Price Nears Key Support RCAT Q1 2026 Earnings Negative EPS Surprise as Strategic Initiatives Continue NBTB Q1 2026 Earnings EPS Misses Estimates by 324 Stock Slips Stevanato Group Q1 2026 Earnings EPS Beats Estimates Amid Operational Gains QuinStreet QNST Q1 2026 Earnings EPS Misses Estimates Slightly Stock Gains on Operational Resilience HSAI Q4 2025 Earnings EPS Misses Estimates Stock Declines PhenixFIN Corporation PFX Q1 2026 Earnings EPS Beats Estimates by 25 Amid Flat Revenue Disclosure Morgan Stanley Lowers Polaris PII Price Target to 69 on Rate and Tariff Concerns IMMR Q3 2025 Earnings EPS Beat Drives Positive Market Reaction Licensing Revenue Remains Opaque Adial Pharmaceuticals ADIL Drops 957 as Selling Pressure Mounts Near Key Support